Penitrem A

CAT:
804-HY-N6776
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Penitrem A - image 1

Penitrem A

  • UNSPSC Description:

    Penitrem A is an indole diterpene neurotoxic alkaloid produced by Penicillium, acts as a selective BK channel antagonist with antiproliferative and anti-invasive activities against multiple malignancies. Penitrem A increases the spontaneous release of endogenous glutamate, gamma-aminobutyric acid (GABA) and aspartate from cerebrocortical synaptosomes, and induces tremorgenic syndromes in animals[1][2].
  • Target Antigen:

    Potassium Channel
  • Type:

    Natural Products
  • Related Pathways:

    Membrane Transporter/Ion Channel
  • Applications:

    Cancer-programmed cell death
  • Field of Research:

    Cancer; Neurological Disease
  • Assay Protocol:

    https://www.medchemexpress.com/penitrem-a.html
  • Purity:

    99.0
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O[C@]12[C@]34[C@@H]([C@H]([C@@H](C(C)=C)O[C@@]4([H])CC[C@@]1([C@]5(C(N6)=C7[C@](OC(C)([C@]8([H])[C@@]([C@]9([H])C8)(O)C%10=C7C6=CC(Cl)=C%10CC9=C)C)([H])[C@]5([H])CC2)C)C)O)O3
  • Molecular Weight:

    634.20
  • References & Citations:

    [1]Goda AA, et al. The Maxi-K (BK) Channel Antagonist Penitrem A as a Novel Breast Cancer-Targeted Therapeutic. Mar Drugs. 2018 May 11;16(5).|[2]Norris PJ, et al. Actions of tremorgenic fungal toxins on neurotransmitter release. J Neurochem. 1980 Jan;34(1):33-42.|[3]Jortner BS, et al. Effects of prolonged tremor due to penitrem A in mice. Drug Chem Toxicol. 1986;9(2):101-16. |[4]Breton P, et al. Brain neurotoxicity of Penitrem A: electrophysiological, behavioral and histopathological study. Toxicon. 1998 Apr;36(4):645-55. |[5]Moldes-Anaya A, et al. Neurotoxicity of Penicillium crustosum secondary metabolites: tremorgenic activity of orally administered penitrem A and thomitrem A and E in mice. Toxicon. 2012 Dec 15;60(8):1428-35.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C, 3 years (Powder)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    12627-35-9